### **Improving Population Health Among Adolescents**



## Vaccines Help Protect Adolescents Against Some Serious and Deadly Diseases, Yet Some Adolescent Vaccinations Remain Below Target<sup>1-6</sup>

### **Risks and Complications**



#### **Meningococcal Disease**

- Even with treatment, ~15 out of 100 people who get uncommon but serious meningococcal disease will die<sup>3</sup>
- Among those who survive, 10 to 20% of people will have serious and permanent complications, including brain damage, kidney damage, hearing loss, and amputation of arms, legs, fingers, or toes<sup>3</sup>




#### **HPV**

- HPV is the most common sexually transmitted infection in the US<sup>4</sup>
- HPV can lead to 6 types of cancer, including cervical cancer<sup>4</sup>



#### **Pertussis (Whooping Cough)**

- 18,617 cases of whooping cough were reported in the US in 2019<sup>5</sup>
- Serious complications of whooping cough in adolescents can include pneumonia; some may need care in the hospital if complications are serious<sup>6</sup>



HPV=human papilloma virus; MenACWY=meningococcal ACWY; MenB=serogroup B meningococcal disease; NIS=National Immunization Survey; Tdap=tetanus, diphtheria, acellular pertussis; UTD=up to date.

References: 1. Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13–17 years—National Immunization Survey-Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912–919. 2. Healthy People 2030. Vaccination. Accessed April 1, 2024. https://www.nfid.org/infectious-objectives-and-data/browse-objectives/vaccination 3. National Foundation for Infectious Diseases. December 2023. Accessed April 1, 2024. https://www.nfid.org/infectious-diseases/meningococcal-di

<sup>\*</sup>Adolescents in the 2022 NIS-Teen were born during January 7, 2004-January 10, 2010.1

<sup>&</sup>lt;sup>†</sup>Healthy People 2030 target for adolescents aged 13-15 years.<sup>2</sup>

<sup>&</sup>lt;sup>†</sup>Includes percentages receiving Tdap vaccine at age ≥10 years.<sup>1</sup>

<sup>&</sup>lt;sup>5</sup>Includes percentages receiving MenACWY or an unknown type of meningococcal vaccine.

<sup>&</sup>quot;HPV UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years. There were ≥5 months minus 4 days between the first and second dose. This update to the HPV recommendation occurred in December 2016.1

<sup>&</sup>lt;sup>1</sup>≥2 doses of MenACWY or unknown type of meningococcal vaccine among adolescents aged 17 years at interview and does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.¹

<sup>\*\*</sup>Calculated only among adolescents who were aged 17 years at time of interview with vaccine administered based on individual clinical decision.1

## **Prioritizing Immunizations Across Quality Programs**



# On-Time Vaccination Is Essential for Protection Against Vaccine-Preventable Diseases, and Most Quality Programs Include Specific Measures for Adolescence<sup>1-6</sup>

		Quality Payment Program		
Quality Measures	NCQA HEDIS <sup>1</sup>	MIPS <sup>2</sup>	MVP <sup>2</sup>	Medicaid Core <sup>3</sup>
Vaccine Specific				
Immunization for Adolescents*	<b>Ø</b>	•		<b>②</b>
Vaccine Relevant				
Child and Adolescent Well-Care Visits*	<b>Ø</b>			<b>Ø</b>
CAHPS Survey	<b>Ø</b>	<b>Ø</b>	<b>⊘</b> †	<b>Ø</b>

The CDC/ACIP/AAP recommend **on-time routine immunization** with all childhood vaccines according to the CDC schedule.<sup>7,8</sup>

AAP=American Academy of Pediatrics; ACIP=Advisory Committee on Immunization Practices; CAHPS=Consumer Assessment of Healthcare Providers and Systems; CDC=Centers for Disease Control and Prevention; HEDIS=Healthcare Effectiveness Data and Information Set; MIPS=Merit-Based Incentive Payment System; MVP=MIPS Value Pathway; NCQA=National Committee for Quality Assurance.

References: 1. NCQA. Summary table of measures, product lines and changes. Accessed April 1, 2024. https://www.ncqa.org/wp-content/uploads/Summary-Table-of-idendesures-Product-Lines-and-Changes.pdf 2. CMS. Medicare and Medicaid programs; CY 2024 payment policies; under the Physician Fee Schedule and other changes to Part B payment and coverage policies; Medicare Advantage; Medicare Advantage; Medicare and Medicaid supplier Enrollment policies; and Basic Health and Coverage policies; Medicare Advantage; Medicare and Medicaid supplier Enrollment policies; and Basic Health and Captures-Program 2023. Accessed April 1, 2024. November 2, 2023. Accessed April 1, 2024. November 3. Medicaid.gov/sites/default/files/2023-24184.pdf 3. Medicaid.gov/sites/default/files/2023-


<sup>\*</sup>Includes race and ethnicity stratification.4.5

<sup>&</sup>lt;sup>†</sup>MVPs include Advancing Cancer Care, Adopting Best Practices and Promoting Patient Safety within Emergency Medicine, and Value in Primary Care.<sup>2</sup>

### **Working with Pfizer**



Pfizer Takes an Integrated, Collaborative Approach to Provide Resources to Help Organizations **Improve Their Vaccination Rates** 



HIT Account Directors, Field Sales, Retail Pharmacy, Field Medical, and Pfizer Navigator teams assist the Vaccine Account Management team with pull-through of vaccine initiatives at the provider and individual practitioner level

© 2024 Pfizer Inc.